elranatamab
pfizer
['elranatamab']
noopur raje presents elranatamab as a new bcma driven bispecific t cell engager - in 55 heavily pretreated pts, no grade 3 crs and response rate 64%. drug can be given q2 weekly. will likely be next bcma bispecific #ash22. #mediq22ash 
Hematologist, Myeloma Expert, Communication Enthusiast. Professor at TGen/City of Hope and Chief Medical Officer of the International Myeloma Foundation